Open for inclusion

Phase Ib, open-label, multicenter dose-escalation study followed by an extension phase to evaluate the safety pharmacokinetics and activity of RO5479599 a glycoengineered antibody against HER3, administered incombination with pertuzumab and paclitaxel in

Cancer type: Breast cancer

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, breast cancer, HER2, HER3

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT01918254?term=BP28752&rank=1